Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 9/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11267211 | 0.75 | HCAR2 (0.62) | HCAR2HCAR3 | |
| Hydrochloric Acid SCHEMBL11394217 | 0.73 | HCAR2 (0.61) | HCAR2HCAR3 | |
| SCHEMBL2360470 | 0.72 | HCAR2 (0.52) | HCAR2CYP3A4L3MBTL1HCAR3 | |
| SCHEMBL11394211 | 0.70 | HCAR2 (0.43) | HCAR2HCAR3 | |
| SCHEMBL11435557 | 0.70 | HCAR2 (0.43) | HCAR2HCAR3 | |
| SCHEMBL2827758 | 0.70 | HCAR2 (0.36) | HCAR2HCAR3 | |
| SCHEMBL377046 | 0.70 | HCAR2 (0.32) | HCAR2HCAR3 | |
| SCHEMBL11495455 | 0.69 | — | — | |
| SCHEMBL3889384 | 0.68 | ALPL (0.32) | HCAR2HCAR3 | |
| Water SCHEMBL7303697 | 0.68 | HCAR2 (0.32) | HCAR2HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969589-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | claimed |
| US-20130165665-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | US | claimed |
| US-8969589-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2794574-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20130165665-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2013096501-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165665-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | HCAR2 296/4885PTGDR 5/4885PTGDR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.